Securities Code: 300009 Securities Abbreviation: Anke Bio Announcement No.: 2026-030
Anhui Anke Bio-High Tech (Group) Co., Ltd.
Announcement on Exclusive Distribution of Mepyramine Maleate Oral Solution
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
To continuously enrich the Company's product pipeline, broaden its pediatric treatment area, and enhance its profitability, Anhui Anke Bio-High Tech (Group) Co., Ltd. (hereinafter referred to as the "Company"), its wholly-owned subsidiary Anhui Huasheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui Huasheng"), Hefei Yigong Pharmaceutical Co., Ltd. (hereinafter referred to as "Hefei Yigong"), and its wholly-owned subsidiary Hefei Enright Pharmaceutical Co., Ltd. (hereinafter referred to as "Enright") have recently reached a strategic cooperation and signed the "Mepyramine Maleate Oral Solution National Exclusive Distribution Agreement." Enright authorizes Anhui Huasheng to be the sole national distributor of the cooperation product Mepyramine Maleate Oral Solution, fully responsible for the market promotion and sales of the cooperation product throughout the People's Republic of China (including mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region). The cooperation period for this product will be from the effective date of this agreement until December 31, 2042 (i.e., the expiration date of the relevant patent protection period for the cooperation product). Upon expiration of the contract, Anhui Huasheng has the priority to renew the contract under the same conditions.
Hefei Yigong and Enright are not related parties to the Company. In accordance with the "Shenzhen Stock Exchange GEM Stock Listing Rules," "Company Articles of Association," and other regulations, this matter does not require submission to the Board of Directors or Shareholders' Meeting for deliberation.
I. Basic Information of Cooperation Parties
- Hefei Yigong Pharmaceutical Co., Ltd.
Legal Representative: He Guangwei
Registered Capital: RMB 64,726,923
Date of Establishment: December 16, 1994
Address: Room D8-404, Jisi Space, 800 Wangjiang West Road, High-tech Zone, Hefei City
Business Scope: Research and development of biomedical engineering, technology transfer, technical consulting, technical services; research and development, production, sales, and technology transfer of disinfection products (excluding hazardous chemicals); import and export of goods or technology (excluding goods or technology prohibited or restricted by national laws and regulations). (For projects subject to approval according to law, business activities can only be carried out after approval by relevant departments).
As of the date of this announcement, the equity structure is as follows: